1. A therapy for suppressing canonical and noncanonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response.
- Author
-
Leibel, SL, McVicar, RN, Murad, R, Kwong, EM, Clark, AE, Alvarado, A, Grimmig, BA, Nuryyev, R, Young, RE, Lee, JC, Peng, W, Zhu, YP, Griffis, E, Nowell, CJ, James, B, Alarcon, S, Malhotra, A, Gearing, LJ, Hertzog, PJ, Galapate, CM, Galenkamp, KMO, Commisso, C, Smith, DM, Sun, X, Carlin, AF, Sidman, RL, Croker, BA, Snyder, EY, Leibel, SL, McVicar, RN, Murad, R, Kwong, EM, Clark, AE, Alvarado, A, Grimmig, BA, Nuryyev, R, Young, RE, Lee, JC, Peng, W, Zhu, YP, Griffis, E, Nowell, CJ, James, B, Alarcon, S, Malhotra, A, Gearing, LJ, Hertzog, PJ, Galapate, CM, Galenkamp, KMO, Commisso, C, Smith, DM, Sun, X, Carlin, AF, Sidman, RL, Croker, BA, and Snyder, EY
- Abstract
The prevalence of "long COVID" is just one of the conundrums highlighting how little we know about the lung's response to viral infection, particularly to syndromecoronavirus-2 (SARS-CoV-2), for which the lung is the point of entry. We used an in vitro human lung system to enable a prospective, unbiased, sequential single-cell level analysis of pulmonary cell responses to infection by multiple SARS-CoV-2 strains. Starting with human induced pluripotent stem cells and emulating lung organogenesis, we generated and infected three-dimensional, multi-cell-type-containing lung organoids (LOs) and gained several unexpected insights. First, SARS-CoV-2 tropism is much broader than previously believed: Many lung cell types are infectable, if not through a canonical receptor-mediated route (e.g., via Angiotensin-converting encyme 2(ACE2)) then via a noncanonical "backdoor" route (via macropinocytosis, a form of endocytosis). Food and Drug Administration (FDA)-approved endocytosis blockers can abrogate such entry, suggesting adjunctive therapies. Regardless of the route of entry, the virus triggers a lung-autonomous, pulmonary epithelial cell-intrinsic, innate immune response involving interferons and cytokine/chemokine production in the absence of hematopoietic derivatives. The virus can spread rapidly throughout human LOs resulting in mitochondrial apoptosis mediated by the prosurvival protein Bcl-xL. This host cytopathic response to the virus may help explain persistent inflammatory signatures in a dysfunctional pulmonary environment of long COVID. The host response to the virus is, in significant part, dependent on pulmonary Surfactant Protein-B, which plays an unanticipated role in signal transduction, viral resistance, dampening of systemic inflammatory cytokine production, and minimizing apoptosis. Exogenous surfactant, in fact, can be broadly therapeutic.
- Published
- 2024